NextEra targets high end of $3.92-$4.02 2026 adjusted EPS range while projecting 8%+ CAGR through 2032
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors
Strategic acquisitions are deepening customer relationships while AI integration boosts lab productivity, positioning the company for durable margin expansion.
- Thermo Fisher raised full-year organic revenue growth outlook to 4%
- Accelerating research funding to provide durable multiyear visibility
- Targeted acquisitions expand clinical trial data platforms and research services
Top Lawyers Discuss 'Bluster', Reality In Proxy Fights
Kai Liekefett, partner & co-chair of shareholder activism practice at Sidley Austin, and Rebecca Van Derlaske, partner in the shareholder activism group at Olshan Frome Wolosky, join Dani Burger on…